AAAAAA

   
Results: 1-25 | 26-43
Results: 1-25/43
DISPOSITION OF 2 TETRAMETHYLCYCLOPROPANE ANALOGS OF VALPROMIDE IN THEBRAIN, LIVER, PLASMA AND URINE OF RATS
Authors: BLOTNIK S BERGMAN F BIALER M
Citation: S. Blotnik et al., DISPOSITION OF 2 TETRAMETHYLCYCLOPROPANE ANALOGS OF VALPROMIDE IN THEBRAIN, LIVER, PLASMA AND URINE OF RATS, European journal of pharmaceutical sciences, 6(2), 1998, pp. 93-98
EXISTING AND NEW CRITERIA FOR BIOEQUIVALENCE EVALUATION OF NEW CONTROLLED-RELEASE (CR) PRODUCTS OF CARBAMAZEPINE
Authors: BIALER M ARCAVI L SUSSAN S VOLOSOV A YACOBI A MOROS D LEVITT B LAOR A
Citation: M. Bialer et al., EXISTING AND NEW CRITERIA FOR BIOEQUIVALENCE EVALUATION OF NEW CONTROLLED-RELEASE (CR) PRODUCTS OF CARBAMAZEPINE, Epilepsy research, 32(3), 1998, pp. 371-378
VALNOCTAMIDE, VALPROMIDE AND VALNOCTIC ACID ARE MUCH LESS TERATOGENICIN MICE THAN VALPROIC ACID
Authors: RADATZ M EHLERS K YAGEN B BIALER M NAU H
Citation: M. Radatz et al., VALNOCTAMIDE, VALPROMIDE AND VALNOCTIC ACID ARE MUCH LESS TERATOGENICIN MICE THAN VALPROIC ACID, Epilepsy research, 30(1), 1998, pp. 41-48
DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE
Authors: BIALER M LEVY RH PERUCCA E
Citation: M. Bialer et al., DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE, Therapeutic drug monitoring, 20(1), 1998, pp. 56-59
CRITERIA TO ASSESS IN-VIVO PERFORMANCE AND BIOEQUIVALENCE OF GENERIC CONTROLLED-RELEASE FORMULATIONS OF CARBAMAZEPINE
Authors: BIALER M YACOBI A MOROS D LEVITT B HOULE JM MUNSAKA MS
Citation: M. Bialer et al., CRITERIA TO ASSESS IN-VIVO PERFORMANCE AND BIOEQUIVALENCE OF GENERIC CONTROLLED-RELEASE FORMULATIONS OF CARBAMAZEPINE, Epilepsia, 39(5), 1998, pp. 513-519
ISOLATION OF N,N-DIALKYLATED DERIVATIVES OF VALPROYLGLYCINAMIDE FROM DOG PLASMA BY ACTIVE CHARCOAL ADSORPTION AND THEIR QUANTIFICATION BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
Authors: SPIEGELSTEIN O BIALER M YAGEN B
Citation: O. Spiegelstein et al., ISOLATION OF N,N-DIALKYLATED DERIVATIVES OF VALPROYLGLYCINAMIDE FROM DOG PLASMA BY ACTIVE CHARCOAL ADSORPTION AND THEIR QUANTIFICATION BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography B. Biomedical sciences and applications, 698(1-2), 1997, pp. 195-200
PRENATAL-DIAGNOSIS OF PSEUDOTHALIDOMIDE SYNDROME IN CONSECUTIVE PREGNANCIES OF A CONSANGUINEOUS COUPLE
Authors: PETRIKOVSKY BM GROSS B BIALER M SOLAMANZADEH K SIMHAEE E
Citation: Bm. Petrikovsky et al., PRENATAL-DIAGNOSIS OF PSEUDOTHALIDOMIDE SYNDROME IN CONSECUTIVE PREGNANCIES OF A CONSANGUINEOUS COUPLE, Ultrasound in obstetrics & gynecology, 10(6), 1997, pp. 425-428
CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996)
Authors: BIALER M JOHANNESSEN SI KUPFERBERG HJ LEVY RH LOISEAU P PERUCCA E
Citation: M. Bialer et al., CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996), Epilepsy research, 26(3), 1997, pp. 465-465
THE DISPOSITION OF VALPROYL GLYCINAMIDE AND VALPROYL GLYCINE IN RATS
Authors: BLOTNIK S BERGMAN F BIALER M
Citation: S. Blotnik et al., THE DISPOSITION OF VALPROYL GLYCINAMIDE AND VALPROYL GLYCINE IN RATS, Pharmaceutical research, 14(7), 1997, pp. 873-878
PHARMACOKINETICS AND ANTIEPILEPTIC ACTIVITY OF VALPROYL HYDROXAMIC ACID-DERIVATIVES
Authors: LEVI M YAGEN B BIALER M
Citation: M. Levi et al., PHARMACOKINETICS AND ANTIEPILEPTIC ACTIVITY OF VALPROYL HYDROXAMIC ACID-DERIVATIVES, Pharmaceutical research, 14(2), 1997, pp. 213-217
OVARIAN NEOPLASM AND ENDOMETRIOID CARCINOMA IN A PATIENT WITH TURCOT-SYNDROME
Authors: SHALON L MARKOWITZ J BIALER M KAHN E WEINBLATT M GIARDIELLO FM LUCE MC DAUM F
Citation: L. Shalon et al., OVARIAN NEOPLASM AND ENDOMETRIOID CARCINOMA IN A PATIENT WITH TURCOT-SYNDROME, Journal of pediatric gastroenterology and nutrition, 25(2), 1997, pp. 224-227
PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF 2 NEW ISOMERS OF N-VALPROYL GLYCINAMIDE
Authors: HADAD S BIALER M
Citation: S. Hadad et M. Bialer, PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF 2 NEW ISOMERS OF N-VALPROYL GLYCINAMIDE, Biopharmaceutics & drug disposition, 18(7), 1997, pp. 557-566
A HOMOZYGOUS HPMS2 MUTATION IN 2 PATIENTS WITH TURCOT-SYNDROME (TS)
Authors: LUCE M KAHN E BIALER M SHALON L MARKOWITZ J
Citation: M. Luce et al., A HOMOZYGOUS HPMS2 MUTATION IN 2 PATIENTS WITH TURCOT-SYNDROME (TS), Laboratory investigation, 76(1), 1997, pp. 21-21
STEREOSELECTIVE PHARMACOKINETIC ANALYSIS OF VALNOCTAMIDE IN HEALTHY-SUBJECTS AND IN PATIENTS WITH EPILEPSY
Authors: BAREL S YAGEN B SCHURIG V SOBACK S PISANI F PERUCCA E BIALER M
Citation: S. Barel et al., STEREOSELECTIVE PHARMACOKINETIC ANALYSIS OF VALNOCTAMIDE IN HEALTHY-SUBJECTS AND IN PATIENTS WITH EPILEPSY, Clinical pharmacology and therapeutics, 61(4), 1997, pp. 442-449
SINGLE-NEEDLE INSERTION TECHNIQUE FOR THORACENTESIS FOR BILATERAL PLEURAL EFFUSIONS
Authors: PETRIKOVSKY B GROSS B SPINAZZOLA R BIALER M
Citation: B. Petrikovsky et al., SINGLE-NEEDLE INSERTION TECHNIQUE FOR THORACENTESIS FOR BILATERAL PLEURAL EFFUSIONS, Fetal diagnosis and therapy, 11(1), 1996, pp. 26-31
PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE
Authors: BIALER M JOHANNESSEN SI KUPFERBERG HJ LEVY RH LOISEAU P PERUCCA E
Citation: M. Bialer et al., PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE, Epilepsy research, 25(3), 1996, pp. 299-319
PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF TETRAMETHYLCYCLOPROPANE ANALOGS OF VALPROMIDE
Authors: BIALER M HADAD S KADRY B ABDULHAI A HAJYEHIA A STERLING J HERZIG Y YAGEN B
Citation: M. Bialer et al., PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF TETRAMETHYLCYCLOPROPANE ANALOGS OF VALPROMIDE, Pharmaceutical research, 13(2), 1996, pp. 284-289
THE CLINICAL PHARMACOKINETICS OF THE NEWER ANTIEPILEPTIC DRUGS - FOCUS ON TOPIRAMATE, ZONISAMIDE AND TIAGABINE
Authors: PERUCCA E BIALER M
Citation: E. Perucca et M. Bialer, THE CLINICAL PHARMACOKINETICS OF THE NEWER ANTIEPILEPTIC DRUGS - FOCUS ON TOPIRAMATE, ZONISAMIDE AND TIAGABINE, Clinical pharmacokinetics, 31(1), 1996, pp. 29-46
CLINICAL SPECTRUM IN HOMOZYGOTES AND COMPOUND HETEROZYGOTES INHERITING CYSTIC-FIBROSIS MUTATION 3849-GREATER-THAN-T - SIGNIFICANCE FOR GENETICISTS (VOL 58, PG 356, 1995)(10KBC)
Authors: GILBERT F LI Z ARZIMANOGLOU I BIALER M DENNING C GORVOY J HONOROF J ORES C QUITTELL L ROSSOFF L VALVERDE K
Citation: F. Gilbert et al., CLINICAL SPECTRUM IN HOMOZYGOTES AND COMPOUND HETEROZYGOTES INHERITING CYSTIC-FIBROSIS MUTATION 3849-GREATER-THAN-T - SIGNIFICANCE FOR GENETICISTS (VOL 58, PG 356, 1995)(10KBC), American journal of medical genetics, 64(3), 1996, pp. 527-527
PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF (E)-2-ENE VALPROYL DERIVATIVES OF GLYCINE AND VALPROYL DERIVATIVES OF NIPECOTIC ACID
Authors: BIALER M KADRY B ABDULHAI A HAJYEHIA A STERLING J HERZIG Y SHIRVAN M
Citation: M. Bialer et al., PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF (E)-2-ENE VALPROYL DERIVATIVES OF GLYCINE AND VALPROYL DERIVATIVES OF NIPECOTIC ACID, Biopharmaceutics & drug disposition, 17(7), 1996, pp. 565-575
DISPOSITION OF VALPROMIDE, VALPROIC ACID, AND VALNOCTAMIDE IN THE BRAIN, LIVER, PLASMA, AND URINE OF RATS
Authors: BLOTNIK S BERGMAN F BIALER M
Citation: S. Blotnik et al., DISPOSITION OF VALPROMIDE, VALPROIC ACID, AND VALNOCTAMIDE IN THE BRAIN, LIVER, PLASMA, AND URINE OF RATS, Drug metabolism and disposition, 24(5), 1996, pp. 560-564
PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE
Authors: STABLES JP BIALER M JOHANNESSEN SI KUPFERBERG HJ LEVY RH LOISEAU P PERUCCA E
Citation: Jp. Stables et al., PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE, Epilepsy research, 22(3), 1995, pp. 235-246
PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF N-VALPROYL DERIVATIVES OF GABA AND GLYCINE
Authors: HADAD S BIALER M
Citation: S. Hadad et M. Bialer, PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF N-VALPROYL DERIVATIVES OF GABA AND GLYCINE, Pharmaceutical research, 12(6), 1995, pp. 905-910
MAGNETIC-RESONANCE-IMAGING OF THE CENTRAL-NERVOUS-SYSTEM IN PEDIATRICNEUROFIBROMATOSIS TYPE-1
Authors: TAFF IP ZITO J BIALER M MONTERA L
Citation: Ip. Taff et al., MAGNETIC-RESONANCE-IMAGING OF THE CENTRAL-NERVOUS-SYSTEM IN PEDIATRICNEUROFIBROMATOSIS TYPE-1, Annals of neurology, 38(2), 1995, pp. 352-352
CLINICAL SPECTRUM IN HOMOZYGOTES AND COMPOUND HETEROZYGOTES INHERITING CYSTIC-FIBROSIS MUTATION 3849-GREATER-THAN-T - SIGNIFICANCE FOR GENETICISTS(10KBC)
Authors: GILBERT F LI Z ARZIMANOGLOU I BIALER M DENNING C GORVOY J HONOROF J ORES C QUITTELL L ROSSOFF L VALVERDE K
Citation: F. Gilbert et al., CLINICAL SPECTRUM IN HOMOZYGOTES AND COMPOUND HETEROZYGOTES INHERITING CYSTIC-FIBROSIS MUTATION 3849-GREATER-THAN-T - SIGNIFICANCE FOR GENETICISTS(10KBC), American journal of medical genetics, 58(4), 1995, pp. 356-359
Risultati: 1-25 | 26-43